Moderna shares drop 7% despite a recent Wolfe Research upgrade, while BioNTech slips 2%
Moderna (NASDAQ:MRNA) stock fell 7% to $148.02 midday Wednesday, giving back a large portion of Tuesday's 14% rally that followed Wolfe Research's upgrade to Peer Perform from Underperform. BioNTech SE (NASDAQ:BNTX) stock also declined 2% to $111.60, suggesting the selloff is largely Moderna-specific. No fresh company news was available to explain Moderna's slide, which appears to be profit-taking after a significant year-to-date surge.
Source:Yahoo财经 · Source Link
Disclaimer: This content reflects only the author’s personal views and does not constitute any investment or financial advice. If you discover any content that violates regulations,Click to Report
24H Trending
-
1
BCUG Coin Analysis: The Current State of Blockchain Cuties Universe Governance Token and Market Liquidity
-
2
CHP Coin Trading Guide: Understanding the Uses and Acquisition Methods of CoinPoker Tokens
-
3
AGGL Coin Value Analysis: Extremely Low Market Activity, Questionable Investment Prospects
-
4
An Analysis of the Current State of Virtual Currency Regulation and Trading Risks in Mainland China
-
5
BCB Coin: Analyzing its Value and Investment Potential
-
6
OGN Trading Depth Analysis: Top 10 Essentials for Beginners
-
7
Virtual Currency Exchange Platforms and Software: Mainstream Choices and Feature Analysis
-
8
What is FEED Coin? An Analysis of the Charity-Oriented Token FEED Project and its Market Status
-
9
Bitcoin Price Continues to Rise: Analysis of Three Core Driving Factors
-
10
PROPS (Propbase) Buying and Trading Guide: Exchange Listings and Market Status Analysis
Markets Today
Recommended Reading












